Artelo Biosciences Launches Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL

Artelo Biosciences has raised $9.475 million through an at-the-market private placement to initiate its Solana treasury strategy, making it the first publicly traded pharmaceutical company to adopt SOL as a core reserve asset. The company plans to use the proceeds to launch its Solana treasury strategy and support ongoing business. Artelo's treasury initiative marks a pivotal step in its long-term growth strategy and positions the company at the intersection of biotechnology innovation and decentralized finance.